Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $118.15 | Total: $590.75 |
| 1 | 10 | $100.08 | Total: $1,000.80 |
| 1 | 25 | $84.79 | Total: $2,119.75 |
| 1 | 50 | $72.28 | Total: $3,614.00 |
| 1 | 100 | $62.55 | Total: $6,255.00 |
Overview
BMS-641988 is a novel nonsteroidal androgen receptor antagonist for the treatment of prostate cancer.
Chemical Properties
| Molecular Formula | C20H20F3N3O5S |
| Molecular Weight | 471.45 |
| CAS Numbers | 1093276-09-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@@]12[C@@]3([C@]([C@@](C)(O1)[C@H](NS(CC)(=O)=O)C2)(C(=O)N(C3=O)C4=CC(C(F)(F)F)=C(C#N)C=C4)[H])[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Rathkopf D, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res. 2011;17[4] 880-887.